Blair S, Bardwell WA, Podbelewicz-Schuller, Mortimer JE. Correlation between hemoglobin and fatigue in women undergoing adjuvant chemotherapy without Erythopoietin-Stimulating Agent (ESA) support. In Press Clinical Breast Cancer.
Gold EB, Pierce JP, Natarajan L, Stefanick ML, Laughlin GA, Caan BJ, Flatt SW, Edmond JA, Madlensky L, Kealey S, Wasserman L, Thomson CA, Rock CL, Parker BA, Jaranja N, Johnes LA, Hollenbach K, Hajek RA, Faerber S, Al-Delaimy W, Mortimer JE. Influence of High Vegetable, Fruit and Fiber Dietary Pattern on Breast Cancer Prognosis by Initial Hot Flash Reporting: The Women’s Healthy Eating and Living (WHEL) Trial. In press J Clin Oncol, 2008.
Dedashti F, Mortimer JE., Trinkaus K, Naughton MJ, Ellis M. Katzenellenbogen JA, Welch MJ, Siegel BA. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2008 Mar 9. [Epub ahead of print].
Loscalzo MJ, Mortimer JE. Reluctant Warriors and Healing Heroes Managing Distress and Maximizing Coping. Coping, 2007; 21, 16.
Liu JX, Eftimie B, Mortimer JE. Intracardiac Metastasis of Germ Cell Tumor Complicated by Pulmonary Hypertension and Thrombocytopenia. J Clin Oncol, 2007; 25:3547–3549.
Mortimer JE, Flatt S, Parker B, Gold E, Wasserman L, Natarajan L, Pierce JP. Tamoxifen, hot flashes and breast cancer recurrences. Breast Cancer Research and Treatment, 2008 Apr;108(3):421-6.
Blair SL, McElroy M, Middleton M, Comstock C, Wolfson T, Mortimer JE, Wallace AM. The efficacy of breast MRI in predicting breast conservation therapy. In press J Surg Oncol, 2008
Mortimer JE, K. Schulman, MS, and J.D. Kohles. Patterns of Bisphosphonate Use in the United States in the Treatment of Metastatic Bone Disease. Clin Breast Cancer 2007; 7(9) 682-689.
Kelsen DP, Ginsberg R, Pajak T, Gunderson L, Sheahan DG, Mortimer J, Estes N, Haller DG, Kocha W, Minsky BD, Roth JA, Willet C. Long-term results of RTOG 8911 (UAS Intergroup 113): A randomized assignment trial comparison of chemotherapy followed by surgery versus surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719-3725.
Mortimer JE. Editorial of “Managing early-stage breast cancer in your older patients.” Oncology 2006; 20:1012-1013.
Govindan R, Wan-Teck L, Arquette MA, Goodner S, Fears C, Mortimer JE, Fracasso PM. Phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Oncology Reports 2006;15: 123-7.
Mortimer JE, Blair SL. Management of early stage breast cancer developing in the elderly. Aging Health 2006; 2:245-251.
Bardwell WA, Natarajan L, Dimsdale JE, Rock CL, Mortimer JE, Hollenbach K, Pierce JP. Cancer-related variables are not associated with depressive symptoms in survivors of early-stage breast cancer. J Clin Oncol 2006;24:2420-2427.
Chantler M, Dolens M, Podbelewicz-Schuller Y, Clark R, Mortimer JE. Change in need for psychosocial support for women with early stage breast cancer. J Psychosocial Oncol 2006;23: 65-77.
Hyman B. Muss, Jamie Von Roenn, Lloyd Earl Damon, Lisa Marie Deangelis, Lawrence E. Flaherty, Paul M. Harari, Karen Kelly, Michael P. Kosty, Matthew J. Loscalzo, Robert Mennel, Beverly S. Mitchell, Joanne E. Mortimer, Franco Muggia, Edith A. Perez, Peter W.T. Pisters, Leonard Saltz, Lidia Schapira, Joseph Sparano. ACCO: ASCO Core Curriculum Outline. J Clin Oncol 2005; 2049-2077.
Fracasso PM, Blum KA, Ma MK, Tan BR, Arquette MA, Picus J, Denes A, Mortimer JE, Wright LP, Goodner SA, Fears CL, Hou V, Ratner L, Ivey Sp, McLeod HL. Phase I study of pegylated liposomal doxorubicin in combination with the multidrug resistance modulator, Valspodar, in advanced malignancies. British J of Cancer 2005;93:46-53.
Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer J, Murphy M, Stewart SJ. Treatment beyond progression in the Herceptin (transtuzumab) pivotal combination chemotherapy trial. J Clin Oncol 2004; 22:1063-1070.
Mortimer JE Cancer Pain: Assessment and Management. New Engl J of Med 2004; 350:201-202.
Mortimer JE and Taylor ME. Positron emission tomography agent 18F-2-deoxy-2-flurou-D-glucose has a therapeutic potential in breast cancer Commentary in Breast Cancer Research and Treatment 2003; 5:329-31.
Mortimer JE and Loscalzo MJ. Management of cancer pain in geriatrics patients – AGS panel – Commentary. J of Supportive Care 2003; 1:184-185.
Mortimer JE, Lauman M, Tan B, Dempsey CL, Shillington AC, Hutchins Ks. Pyridoxine treatment and prevention of Hand Foot Syndrome in patients receiving capecitabine. J Oncol Pharm Prac 2003; 9: 161-166.
Mortimer JE, Urban JH. Review of Long-Term Toxicities of Selective Estrogen Receptor Modulators (SERMs) and Anti-Aromatase Agents. Oncology 2003; 17:652-659.
Mortimer JE. Endocrine therapy for the treatment of breast cancer: Considerations for long-term use. Current Oncology 2003; 10 S1: 30-36.
Mortimer JE. Menopausal Symptoms in Breast Cancer Survivors. Menopause Digest 2003;15:11-13.
Jahanzeb J, Mortimer JE,Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabit T, Kronish L. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with her2+ metastatic breast cancer. The Oncologist 2002; 7:410-417.
Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A Phase I trial of escalating doses of Trastuzumab combined with daily subcutaneous Interleukin-2: Report of Cancer and Leukemia Group B 9661. Clin Ca 2002; 8: 3718-3727.
Mortimer JE. The clinical challenge of menopausal symptoms in breast cancer survivors. Geriatrics 2002; 57:25-31.
Read WL, Picus J, Mortimer JE. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002;94:847-53.
Holland DW, Boucher LD, Mortimer JE. Tubular breast cancer experience at Washington University and review of the literature Breast Cancer 2001;3:210-214.
Taylor ME, Keleti D, Perez CA, Myerson RJ, Halverson KJ, Schechtman KB, Herrmann VM, Mortimer JE, Lockett MA. The effect of medical co-morbidities of diabetes, hypertension and obesity on the incidence of arm edema after breast conservation therapy for Stage I and II breast cancer. Int J Rad and Biophysics in press, 2110.
Mortimer J, Dehdashti F, Siegel BA, et al: Metabolic Flare: An indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19:2797-2803.
Mortimer J. Tamoxifen and Sexuality – Let’s listen to the data speak. J Clin Oncol 1999; 17:3689-3693.
Parnes HL, Conaway M, Isner J, Mortimer JE, et al: Megestrol acetate for the treatment of cachexia in patients with advanced lung or colorectal cancer CA Therapeutics 1999;2:75-82.
Mortimer JE, Boucher L, Baty J, Knapp DL, et al.: Effect of tamoxifen on sexual functioning. J Clin Onc 1999;17:1488-1492.
Dehdashti F, Flanagan F, Mortimer JE, et al.: PET Assessment of “Metabolic Flare” to predict response of metastatic breast cancer to antiestrogen therapy. European J of Nuclear Med 1999 26:51-56.
Kelsen DP, Ginsberg R, Pajak T, Gunderson L, Mortimer J, et al: Preoperative chemotherapy followed by operation versus operation alone for patients with localized esophageal cancers: A U.S. national intergroup study. N Engl J 1998;339:1979-1984.
Glick JH, Griffith RS, Mortimer JE. Chemotherapy: Helping the Patient Cope. Patient Care 1998;49-59.
Mortimer JE, Bajorin D, Buckner J, Leichman CG, Mayer R and Press OW. Training Resource Document for Curriculum Development in Medical Oncology. J Clin Oncol 1998; 16:372-379.
Mortimer JE and Bartlett NL. Assessment of knowledge about cancer pain management by physicians in training. J Pain and Symptom Mgmt 1997;14:21-28.
Miller KD, Loehrer PJ, Gonin R, Ansari R, Pletcher W, McClean J, Spiridonidis CH, Mortimer J. A Phase II Study of Weekly Oral Methotrexate and Zidovudine in Advanced Adenocarcinoma of the Pancreas and Hepatocellular Carcinoma. Investigational New Drugs 1996;14:207-212.
Graham MV, Jahanzeb M, Dresler CM, Cooper JD, Emami B, Mortimer JE. Results of a Trial with Topotecan Dose Escalation and Concurrent Thoracic Radiation Therapy for Locally Advanced Inoperable Nonsmall Cell Lung Cancer. Int J. Radiation Oncology Biol. Phys. 1996;36:1215-1220.
Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ: Positron Emission Tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16(-[18F]Fluoro-17(-estradiol in Breast Cancer: Correlation with Estrogen-Receptor Status and Response to Systemic Therapy. Clinical Cancer Res 1996;2:933-939.
Dehdashti, F., Mortimer, J., Siegel, B., Griffeth, L., Bonasera, T., et al.: Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. The Journal of Nuclear Medicine 1995;36:1766-1774.
Kosty MP, Fleishman SB, Herndon JE, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, green MR. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small cell lung cancer: A randomized placebo-controlled, bouble-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:1113-1120.
Taylor ME, Perez CA, Halverson KJ, Kuske RR, Philpott GW,Garcia DM, Mortimer JE, Myerson RJ, Radford D, Rush C: Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 1994;31:753-764.
Mortimer JE. Pain management in oncology patients. Am Soc Clin Oncol, Biotherapy Report 1994;4-2: 2.
Perez CA, Graham ML, Taylor ME, Levy JF, Mortimer JE, et al: Management of locally advanced carcinoma of the breast. Cancer 1994; 74:453-465.
Mortimer, J., Taylor, M.: Can chemotherapy alter the histologic features of breast cancer? American Journal of Clinical Pathology 1994; 102:147-149.
Grunberg, S.M., Montague, L., Lester, E.P., Sridhar, K.S., Mortimer, J., Murphy, W., Sanderson, P.E.: Randomized, double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 1993.
Beck, T.M., Hesketh, P.J., Madajewicz, S., Navari, R.M., Pendergrass, K., Lester, E.P., Kish, J.A., Murphy, W.K., Hainsworth, J.D., Gandara, D.R., Bricker, L.J., Keller, A.M., Mortimer, J., Galvin, D.V., House, K.W., Bryson, J.C.: Stratified, randomized, double-blind comparison of intravenous Ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10:1969-1975.
Canfield, V., Mortimer, J.E. Chemotherapy in the management of malignant gastrointestinal disease. Gastroenterol Clin North Am 1992; 21:695-714.
Mortimer, J.E., Crowley, J., Eyre, H., Weiden, P., Eltringham, J., Stuckey, W.J.: A Phase II randomized study comparing sequential and combined intra-arterial cisplatin and radiation therapy in primary brain tumors. Cancer 1992; 69:1220-1223.
Jacobs, C., Lyman, G., Velez-Garcia, E., Sridhar, K., Knight, W., Hochster, H., Goodnough, L.T., Mortimer, J.E., Einhorn, L.H., Schacter, L., Cherng, N., Dalton, T., Burroughs, J., Rozencweig, M.: A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257-263.
Mortimer, J.E., Black, D.W., Fijalka, S.: Comparison of cefoperazone and mezlocillin with imipenem/cilastatin in febrile neutropenic patients with cancer. Curr Ther Res 1991; 49:701-710.
Press, O.W., Livingston, R., Mortimer, J.E., Collins, C., Appelbaum, F.: Treatment of relapsed non-Hodgkin’s lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9:423-43l.
Mortimer, J.E., Anderson, I.A.: Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990; 26:449-452.
Mortimer, J.E., Black, D.J.: Antiobiotic therapy for the febrile cancer patient. Hosp Phys 1990; 26:22-26.
Mortimer, J.E., Schulman, S., MacDonald, J.S., Kopecky, K., Goodman, G.: High-dose cisplatin in disseminated melanoma: a comparison of two schedules. Cancer Chemother Pharmacol 1990; 25:373-376.
Budd, G.T., Metch, B., Balcerzak, S.P., Fletcher, W.S., Baker, L.H., Mortimer, J.E. High-dose cisplatin for metastatic soft tissue sarcoma. Cancer 1990; 65:866-869.
Mortimer, J.E., Kidd, P.: Myasthenia gravis and lymphoblastic lymphoma. Anti-acetylcholine receptor antibody as a tumor marker - a case report. Cancer Invest 1989; 7:327-331.
Coldwell, D.M., Mortimer, J.E. Transcatheter therapy for malignant neoplasms. West J Med 1989; 151:299-303.
Collins, C., Mortimer, J.E., Livingston, R.B.: High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer 1989; 63:228-232.
Mortimer, J.E., Blinder, M.A., Schulman, S., Applebaum, F.R., Buckner, C.D., Clift, R.A., Sanders, J.E., Storb, R., Thomas, E.D.: Relapse of acute leukemia after marrow transplantation. Natural history and results of subsequent therapy. J Clin Oncol 1989; 7:50-57.
Mortimer, J.E., Miller, S., Black, D.W., Kwok, K., Kirby, W.M.: Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Amer J Med 1988; 85:17-20.
Mortimer, J.E., Higano, C.: Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. Cancer Invest 1988; 6:129-132.
Mortimer, J.E., Taylor, M.E., Schulman, S., Cummings, C., Weymuller, E., Laramore, G.E.: Feasibility and efficacy of weekly intra-arterial cisplatin in locally advanced (stage III and IV) head and neck cancers. J Clin Oncol 1988; 6:969-975.
Marglin, S.I., Mortimer, J.E., Castellino, R.A.: Radiologic investigation of thoracic metastases from unknown primary sites. J Thorac Imag 1987; 2:348-43.
Appelbaum, R.R., Sullivan, K.M., Thomas, E.D., Flournoy, N., Buckner, C.D., Clift, R.A., Deeg, J., Fefer, A., Hill, R., Mortimer, J., Neiman, P.E., Sanders, J.E., Singer, J., Stewart, P., Storb, R.: Treatment of malignant lymphoma in one hundred patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol 1987; 5:1340-1347.
Mortimer, J.E., Blinder, M.A., Black, D., Kwok, K., Miller, S.A.: Comparison of double beta-lactam antibiotics (cefoperazone/mezlocillin or cefperazone/piperacillina) with ticarcillin, tobramycin and cefazolin in febrile neutropenic patients. Curr Ther Res 1987; 42:25-33.
Tallman, M.S., Appelbaum, M.D., Amos, D., Goldberg, M.D., Livingston, R.B., Mortimer, J.E., Weiden, P.L., Thomas, E.D.: Evaluation of intensive post-remission chemotherapy for adults with acute non-lymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. J Clin Oncol 1987; 5:9l8-926.
Mortimer, J., Flournoy, N., Livingston, R.B., Stephens, R.L.: Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer: results of Southwest Oncology Group trial. Cancer 1985; 56:2376-2380.
Mortimer, J., Livingston, R.B., Hardesty, I.J., Groppe, C.W., Jr., Purvis, J.D. III, Gupta, M., Flournoy, N.: Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer. Cancer Treat Rep 1984; 68:l0l7-l0l8.
Mortimer, J. Cancer followup. A guide to care after successful treatment. Consultant 1984; 24:202-2ll.
Mortimer, J.E., Hewlett, J.S., Bay, J., Livingston, R.B., Bone Marrow Transplant Team: High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas. J Neuro-Oncol 1983; l:269-273.
Mortimer, J., Bukowski, R.M., Montie, J., Hewlett, J.S., Livingston, R.B.: VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms. Cancer Chemother Pharmacol 1982; 7:215-218.
Mortimer, J., Reimer, R., Greenstreet, R., Groppe, C., Bukowski, R.: Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer. Cancer Treat Rep 1981; 65:763-766.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 06/08.
